MARKETS / NYSE / SDEV
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Stablecoin Development Corporation SDEV

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
Dividend / sh · FY25
$4.00
Payout · FY25
-1%
ROE · FY25
Net margin · FY25
Dividend coverage
-27.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.0050.010.0150.02-0.62009201220152018202120242025
0.0050.010.0150.02-0.62016201920222025

Per share
Diluted EPS, FY2025
EPS Dividend
800016000240004.002009201220152018202120242025
800016000240004.002016201920222025

The dividend was paid in a year without profit.

Profitability
Return on equity, FY2025
ROE
0.250.50.7512009201220152018202120242025
0.250.50.7512016201920222025
Operating margin
Net margin
Return on assets-10126.5%

Returned to shareholders
USD 4.8M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 4.8M
Net buybacks
Share of profit-0.8%
Consecutive raises

USD 4.8M in dividends went back to shareholders in a year without profit.

Growth
+8.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.4%
+8.2%
+25.0%
−3.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.03B
Shares outstanding, FY2025
0.020.032009201220152018202120242025
0.020.032016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.0M
total assets, end of FY2025
Total assetsUSD 9.0M
EquityUSD -631.8M
CashUSD 8.0M
Current ratio7.60×

Equity funds -6993% of total assets.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.6
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
·
·
·
·
−150.00
−310.00
−480.00
−0.46
−0.48
−1.40
−6.82
−7.65
−10.51
−0.24
−0.20
−0.18
23115.00
Dividend / sh $
4.00
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−1
−0
·
·
·
·
−0
·
·
·
·
·
·
·
·
·
·
ROE %
·
−453.6
−139.0
−102.4
−51.8
−166.1
−325.9
−173.4
−152.7
−1313.1
·
−822.2
·
·
·
·
·
Shares out B
0.03
0.00
0.00
0.00
0.00
0.04
0.03
0.02
0.02
0.02
0.00
0.00
0.04
0.04
0.03
0.02
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
59 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 3 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed